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Abstract
Background
Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human
VEGF. Several studies have investigated the effectiveness of bevacizumab therapy accord-
ing to different cancer types but these days there is an intense debate on its utility. We have
investigated different methods to find the best tumor volume estimation since it creates the
possibility for precise and effective drug administration with a much lower dose than in the
protocol.
Materials and Methods
We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal ade-
nocarcinoma. In both cases, three groups were compared in the experiments. The first
group did not receive therapy, the second group received one 200 μg bevacizumab dose
for a treatment period (protocol-based therapy), and the third group received 1.1 μg bevaci-
zumab every day (quasi-continuous therapy). Tumor volume measurement was performed
by digital caliper and small animal MRI. The mathematical relationship between MRI-mea-
sured tumor volume and mass was investigated to estimate accurate tumor volume using
caliper-measured data. A two-dimensional mathematical model was applied for tumor vol-
ume evaluation, and tumor- and therapy-specific constants were calculated for the three dif-
ferent groups. The effectiveness of bevacizumab administration was examined by
statistical analysis.
Results
In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly
smaller tumor volume compared to the no treatment group; however, there was a significant
difference between untreated mice and mice who received quasi-continuous therapy (p =
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0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total
dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038).
When the tumor has a symmetrical, solid closed shape (typically without treatment), volume
can be evaluated accurately from caliper-measured data with the applied two-dimensional
mathematical model.
Conclusion
Our results provide a theoretical background for a much more effective bevacizumab treat-
ment using optimized administration.
Introduction
Bevacizumab (Avastin) [1] is an exogenous inhibitor, which inhibits the biological activity of
human VEGF [2]. Several studies have investigated the effectiveness of bevacizumab therapy
according to different types of cancer [3]: lung cancer [4, 5], breast cancer [6–8], colon cancer
[9], renal cell carcinoma [10], gastric cancer [11], pancreatic cancer [12], prostate cancer [13]
and melanoma [14]. The majority of debate over Avastin is about breast cancer because, in
2011, the US Food and Drug Administration (FDA) revoked the approval of Avastin for breast
cancer treatment in the absence of decisive therapeutic benefit; however, several clinical trials
suggested that Avastin can be effective in breast cancer treatment [6, 7].
The 1st Department of Pathology and Experimental Cancer Research of the Semmelweis
University (Budapest, Hungary) and the Physiological Controls Group of the Obuda Univer-
sity (Budapest, Hungary) began collaborating on antiangiogenic therapy research in 2012—
including the current experimental investigations. Small MRI measurements were done in the
Preclinical Imaging Center of Gedeon Richter Plc. (Budapest, Hungary). The aim of the experi-
ment was to create and validate a clinically relevant tumor growth model (using C38 colon ade-
nocarcinoma), focusing on the effect of angiogenesis. Tumor growth was investigated without
therapy and with antiangiogenic therapy (using bevacizumab [15]). Examination of tumor
growth belongs not only to the basic medical research, but to the biomedical engineering field
as well. Based on the experimental data, model identification can be carried out which describes
the mathematical model of the investigated biological process. Using the mathematical model,
different dosage algorithms can be designed for antiangiogenic cancer therapy [16–19]. Due to
the collaboration between medical doctors and biomedical engineers, model-based treatment
protocols can be created. These model-based protocols can be more effective than the current
ones, since they provide individual treatment for the patients.
The article discusses two results. First is to find an appropriate mathematical model for
tumor volume evaluation from caliper-measured data. Tumor as a 3-D object has three diame-
ters (width, length and height); however in vivo only two diameters can be measured by caliper
(width, w and length, l). To evaluate tumor volume, first the shape of the tumor has to be
assumed, and if it is necessary for volume calculation, the third diameter (height, h) has to be
approximated. According to the Xenograft tumor model protocol [20], tumor volume has to be
calculated using the following formula:
V ¼ w2  l
2
: ð1Þ
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The advantage of this model is that there is no need to approximate tumor height (which
could result in error).
In several recent studies ([21, 22]), tumor volume is calculated assuming ellipsoid shape:
V ¼ 4
3
 p  l
2
 w
2
 h
2
: ð2Þ
Whilst studies have shown that tumors can be better estimated with ellipsoid shape than
using Eq 1, calculating the volume of an ellipsoid requires the knowledge of the third parame-
ter. A possible solution for height approximation [23] is:
h ¼ 2
3
 l: ð3Þ
Another relatively new but not widely used approach to estimate tumor volume is to assume
hemi-ellipsoid shape [24]. In this case, tumor volume has to be calculated in the following way:
V ¼ p  l
2
 w
2
 h
2
: ð4Þ
This estimation has the same disadvantage as ellipsoid estimation, i.e. tumor height has to
be approximated.
From the abovementioned methods, the consequence is that the promising new direction in
tumor volume evaluation is the dimension reduction, namely to find a statistical constant
which can replace the need of measuring the tumor height. A two-dimensional mathematical
model was created from the experimental results of BALB/c mice with KHJJ tumor line [25]:
V ¼ p
6
 f  ðl  wÞ3=2; ð5Þ
where f is a constant which belongs to a certain tumor type. This formula was the starting point
of our examination to find an appropriate mathematical model.
The second result which is discussed in the article is comparison of the effectiveness of bevaci-
zumab administration in the case of protocol-based and quasi-continuous therapies. The effec-
tiveness strongly depends on the administration, and a drug which is effective on a molecular
level can be applied in a less effective way because of the incorrectly chosen administration.
Our hypothesis is that the effectiveness of a lower dosage with a quasi-continuous therapy can
be comparable with the protocol therapy.
Materials and Methods
Ethics statement
The study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Hungarian Animal Experimental Research Ethics Council (Állatkísérleti
Tudományos Etikai Tanács, ATET), Permit Number: 22.1/1159/3/2010. All surgery and sacri-
fice were performed under sodium pentobarbital anaesthesia (Nembutal, 70 mg/kg), and all
efforts were made to minimize suffering. Animals were carried out in the most humane and
environmentally sensitive manner possible; in addition the 3Rs principle (replacement, refine-
ment, reduction) was adequately implemented according to the Directive 2010/63/EU of the
European Parliament. Mice were monitored daily. Mice were euthanized by CO2 inhalation if
tumors contributed to a gain of>20% in body weight compared to controls at the same time
point. Mice were humanely sacrificed using cervical dislocation.
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Overview of the phases
The whole experiment consisted of four phases; the article focuses on the Phase III/3 and its
results together with the comparison of Phase I and Phase III/3 (Fig 1).
In Phase I, we have investigated tumor growth without therapy with two types of mouse
tumor. 12 immunocompetent mice were transplanted subcutaneously with C38 colon adenocar-
cinoma, and 11 immunocompetent mice were injected intramuscularly with B16 melanoma.
Tumor volume was measured with digital caliper. Results of this phase can be found in [26].
In Phase II, the toxicology investigation of the applied angiogenic inhibitor (bevacizumab)
was performed; there was no tumor implantation into mice in this phase. We monitored the
vital parameters of 4 immunocompetent mice, and there was no serious toxic side-effect or
lethality regarding to the usage of bevacizumab.
In Phase III, we have investigated C38 colon adenocarcinoma growth with bevacizumab
therapy. Phase III contained three subphases, in every subphases two groups were created; con-
trol group received bevacizumab in one dose according to the protocol, while case group
received substantially lower doses every day. In the first subphase (Phase III/1), control group
members (5 immunocompetent mice) received 10 mg per kg body weight bevacizumab, while
case group members (5 immunocompetent mice) received one-tenth dose of control dose
spread over 18 days. Bevacizumab administration was started on the 7th day in both cases.
Quantity of the optimal solvent administration was also examined in this subphase. Tumor
volume was measured with digital caliper. The second subphase (Phase III/2) was similar to
Phase III/1, mice received the same dosage of bevacizumab as in Phase III/1, however sample
size was higher (6 immunocompetent mice in control group, 12 immunocompetent mice in
case group), and bevacizumab administration started earlier, on the 3rd day of the experiment.
Tumor volume was measured with digital caliper as well. Result of Phase III/2 was that the
effectiveness of the small amount of quasi-continuous dosage is comparable with the effective-
ness of one large dose [23], however this result is only based on caliper-measured data. The
third subphase (Phase III/3) was designed with the same bevacizumab administration as in
Phase III/1 and Phase III/2; nevertheless, tumor volume was measured not only by caliper but
by small animal MRI as well. In this phase, 5 immunocompetent mice in control group, and 9
immunocompetent mice in case group were used.
Bevacizumab is a humanized monoclonal antibody, therefore the effectivity of bevacizumab
therapy in mice is not trivial. Although there are studies which confirme that “bevacizumab is
as effective as the murine anti-VEGF-R2 antibody (DC101) in mouse models” ([27, 28]), we
extended our experiments and performed Phase IV, where immunocompromized (SCID) mice
were used with human colorectal adenocarcinoma (HT-29) xenografts. In this phase, three
groups were created. Mice in the control group received no treatment (5 mice); case1 group
members (10 mice) received 10 mg per kg body weight bevacizumab in one dose; while case2
group members (10 mice) received 1/180 dose of control dose for 15 days. (Fig 2).
Tumor implantation and bevacizumab administration
In Phase I, Phase II and Phase III, eight weeks old male C57Bl/6 mice with implanted C38
mouse colorectal carcinoma was used. In Phase IV, eleven weeks old male SCID mice with
implanted HT-29 human colorectal adenocarcinoma was used. Mice were monitored daily by
personnel experienced in recognizing signs of morbidity (illness, injury, or abnormal behavior)
also in weekends and holidays. The C38 colorectal carcinoma line was maintained by serial
subcutaneous transplantations in C57Bl/6 mice. (Inbred C57Bl/6 mice from our institute were
used throughout the studies.) In Phase I, Phase II and Phase III, a piece of C38 colon adenocar-
cinoma was transplanted subcutaneously in the recipient animal on the 1st day of the
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Fig 1. Overview of Phase I and Phase III/3. In Phase I, tumor growth was investigated without antiangiogenic therapy for 24 days (mice were sacrificed
when the tumor reached a lethal size). In Phase III/3, control group members received one 200 μg bevacizumab dose for an 18-day therapy (on the 3rd and
21st days); case group members received 1.11 μg bevacizumab every day for 20 days.
doi:10.1371/journal.pone.0142190.g001
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Fig 2. Overview of Phase IV. In Phase IV, control group members received no bevacizumab. Case1 group members received one 200 μg bevacizumab
dose on the 8th day, case2 group members received 1.11 μg bevacizumab from the 8th day every day for 15 days.
doi:10.1371/journal.pone.0142190.g002
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experiment (approximately 2106 cells were transplanted into each mouse). In Phase IV,
approximately 2.9106 cells were injected subcutaneously into each SCID mouse. Tumor was
located in the last third of the back of the mouse in every case.
Mice in Phase I and Phase IV control group received no bevacizumab. Mice in Phase III/3
control and case groups, and mice in Phase IV case1 and case2 groups received bevacizumab.
Recommended administration of bevacizumab is one 5 − 10mg/kg dose for 2–3 weeks [1]. We
have administered 10mg/kg body weight intraperitoneally, which means 200 μg bevacizumab
per a mouse, since the mass of the mice in the experiment was approximately 20 g (in the case
of C57Bl/6 and SCID mice as well). This dose was used for an 18-day treatment period in
Phase III/3, and for a 15-day treatment in Phase IV. In Phase III/3, control group members
received 200 μg bevacizumab (with 455 μl 0.9% NaCl solution) in one dose intraperitoneally on
the 3rd day and on the 21st day. In Phase III/3, case group members received one-tenth dose of
control dose intraperitoneally spread over 18 days. It means that a mouse of the case group
received 1.11 μg bevacizumab (with 45 μl 0.9% NaCl solution) every day from the 3rd day for
20 days. In Phase IV, case1 group members received 200 μg bevacizumab (with 200 μl 0.9%
NaCl solution) in one dose intraperitoneally on the 8th day. In Phase IV, case2 group members
received 1.11 μg bevacizumab (with 45 μl 0.9% NaCl solution) every day form the 8th day for
15 days. The reason for choosing this type of administration was as follows: a) we wanted to
use a daily dose in order to investigate the biological effect of frequent impulse-like control sig-
nal for the future controller design; b) we wanted to examine such a low dose which has practi-
cally no side-effect but presumably is still effective.
Tumor volume measurement
Tumor volume measurement cannot happen right after tumor implantation. In the case of C38
colon adenocarcinoma, first, the subcutaneously transplanted piece of tumor has to disinte-
grate, and after that the new tumor colony (which needs to be measured) can begin to grow
from the disintegrated tumor cells. This process takes 4–5 days. The first measurement in
Phase I occurred on the 5th day; in Phase III/3, it occurred on the 4th day. In Phase IV, the first
measurement occurred when the tumors have reached an average volume of 50–60mm3
(according to the xenograft protocol [20]). It was on the 10th day, since HT-29 colorectal ade-
nocarcinoma grows slower in mice than C38 colon adenocarcinoma.
Tumor volume was measured in two different ways. First way is the caliper measurement;
in that case tumor diameters (width, length) are measured with digital caliper. It can be carried
out in vivo during the experiment due to the subcutaneous localization of the tumor. Tumor
volume (and the third diameter) has to be approximated, assuming a certain shape for the
tumor. Measurements with caliper were done on the 5th, 8th, 10th, 12th, 15th, 17th, 19th,
22nd and 24th days of the experiment in Phase I; in the case of Phase III/3, they were done on
the 4th, 6th, 8th, 10th, 12th, 14th, 16th, 18th, 20th, 22nd and 23rd days. In Phase IV, the caliper
measurement days were the 10th, 12th, 17th, 19th, 22nd and 23rd days.
The other way to measure tumor volume is the usage of small animal MRI, a non-invasive
in vivo technology giving the possibility of a more precise volume measurement [29]. In the
experiment 9.4 Tesla field strength Varian small-animal MRI was used. Isofluorane (0.95 x
2.0%) was applied for inhalational anesthesia, and intubation was performed. Catheter was
placed in the tail vein for injection—according to the mouse tail vein injection protocol [30]—
to investigate drug effect. Position of the mouse was fixed to minimize the movement of the
animal. Tumor was located in the last third of the back in every cases, thus the effect of respira-
tory movement was minimal. During the MRI measurements, life parameters of the mice were
monitored. Breathing was monitored with piezoelectric transducer; temperature of the body
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was measured by rectal thermometer. The produced images were converted to NIfTI (Neuro-
imaging Informatics Technology Initiative) format, which is suitable for image processing.
Tumor area was determined with flood fill algorithm [31] from the slides; by knowing the vol-
ume of a voxel, tumor volume was calculated from these two values.
Contrast agents improve the visibility, but it is an extra strain to the organism, which can be
lethal to animals which are in the final stage of cancer. We have found in our previous study
[32] that measurements without contrast agents resulted in high quality images, where tumor
can be circumscribed precisely, thus the usage of contrast is unnecessary. In the case of Phase I
and Phase IV, there were no MRI measurements. Measurements with small animal MRI were
done on the 4th, 8th, 11th, 15th, 18th and 23rd days of the experiment in Phase III/3. In the
first four measurement times 30 slices were done from each mouse; in the last two measure-
ment times 40 slices were done from each mouse due to the larger tumor volume. One can see
experimental settings in Table 1, while MRI image of a control group mouse (C4) that was
measured at the end of the experiment can be found in Fig 3.
Table 1. Experimental settings for small animal MRI measurement.
30 slices 40 slices
Pulse sequence: T1WI, sequence: FSE, Pulse sequence: T1WI, sequence: FSE,
FOV: 25 x 25, spatial resolution: 128 x 128 x 30, FOV: 30 x 30, spatial resolution: 128 x 128 x 40,
voxel size: 0.1953 x 0.1953 x 1 mm, voxel size: 0.2343 x 0.2343 x 1 mm,
TR: 1800 ms, ESP: 7 ms, TR: 2500 ms, ESP: 7 ms,
axial orientation: axial 90°, flip angle: 90°, axial orientation: axial 90°, flip angle: 90°,
averages: 12, scan time: 5 min 53 s averages: 10, scan time: 6 min 45 s
In the first four measurement times 30 slices, in the last two measurement times 40 slices were done from
each mouse. Abbreviations: T1WI: T1 weighted image, FSE: Fast Spin Echo, FOV: Field of View [mm2],
TR: Repetition Time, ESP: Echo Spacing.
doi:10.1371/journal.pone.0142190.t001
Fig 3. MRI slices in the case of a control groupmouse (C4) on the 23rd day of the experiment (Phase III/3).
doi:10.1371/journal.pone.0142190.g003
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Sacrificing mice, immunohistochemistry
Clinical aspects which have to be considered to determine when animals should be euthanized
are body weight, physical appearance, measurable clinical signs, unprovoked behavior and
response to external stimuli. Clinical criteria that establish when the endpoint have to be car-
ried out: a) if tumors contributed to a gain of>20% in body weight compared to controls at the
same time point; b) tumors that ulcerate, become necrotic or infected; c) any animal found
unexpectedly to be moribund, cachectic, or unable to obtain food or water. All surgery and sac-
rifice were performed under sodium pentobarbital anaesthesia (Nembutal, 70 mg/kg). Mice
were humanely sacrificed using cervical dislocation. No animals were sacrificed before the
experimental endpoint. The size of maximum tumor volumes observed in our study fulfills the
requirements of Hungarian animal experimental research protocol.
In Phase I, mice were sacrificed when the tumor reached a lethal size; it was on the 24th day
of the experiment. In the case of Phase III/3 and Phase IV, period of time was specified accord-
ing to the previous phases (Phase I and Phase III/1); mice were sacrificed on the 23rd day of
the experiment. After sacrificing mice, tumors were removed, and their mass was measured.
Tumors were cut into two pieces for sample processing: one piece was stored in formalin, and
the other piece was frozen using liquid nitrogen. Tumor morphology was investigated using
standard Haematoxylin Eosin staining on the samples stored in formalin. Frozen samples were
used to create 15 μm frozen cuts. After fixing in methanol, rat anti-mouse CD31 antibody
(1:50, 550274 BD PHARMINGEN) was applied as primer antibody, and FITC conjugated anti-
rat CD31 antibody (1:100, Jackson Immunoresearch, 712-095-150) was applied on the slides as
secondary antibody. After staining, fluorescence pictures were done from the slides using con-
focal microscope (BIO-RADMRC-1024). These images were applied to calculate vasculariza-
tion area by using ImageJ (NIH, USA) [33] software (Fig 4).
Statistical analysis
To compare the effectiveness of the different investigated treatment methods, statistical analy-
sis was used. PASW Statistics 18 (SPSS Statistics, IBM, USA) and Matlab R2009b (MathWorks,
Fig 4. Stained slices in the case of n1mouse (Phase I, 24th day of the experiment). a) Haematoxylin Eosin (H&E) staining was applied to investigate
tumor morphology. b) Fluorescence picture was created using CD31 antibody immunohistochemistry staining to calculate vascularization area.
doi:10.1371/journal.pone.0142190.g004
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USA) were used for statistical analysis. Normality was investigated with one-sample Kolmogo-
rov-Smirnov test, and homogeneity of variance (homoscedasticity) was examined with
Levene’s test. Analysis of Variance (ANOVA) test was used to compare more than two sam-
ples, while pairwise comparison was done by Tukey’s honest significant difference (HSD) test.
Correlation was investigated with Pearson’s rank correlation test (Pearson’s R) and coefficient
of determination (R2).
Results
In Phase I, 12 mice were implanted with C38 colon adenocarcinoma. One of them died on the
18th day, and another one on the 23rd day. The cause of death was tumor toxicity; however,
none of the clinical criteria for euthanasia could be observed at these animals. In Phase I, 10 mice
were sacrificed at the 24th day of the experiment. In Phase III/3, control group contained 5 mice,
case group contained 9 mice; all mice were implanted with C38 mouse colon adenocarcinoma.
Nomice died during the experiment, therefore 5 mice from the control group, and 9 mice from
the case group were sacrificed on the 23rd day. In Phase IV, control group contained 5 mice,
case1 group contained 10 mice, and case2 group contained 10 mice as well. All mice were
implanted with HT-29 human colorectal adenocarcinoma. In the control group, one mouse died
on the 20th day due to tumor toxicity. In the case1 group, one mouse died on the 17th day.
Autopsy revealed large metastasis in the lung, this is the suspected cause of the death. In the
case2 group, one mouse died on the 8th day, before the therapy (bevacizumab administration)
started. Autopsy revealed only minimal local tumor; however death was not caused by tumor.
Comparing the results of caliper and MRI measurements; finding an
appropriate mathematical model for tumor volume evaluation from
caliper-measured data
In Phase III/3, MRI-measured tumor volume values are available which can be used as refer-
ence values for caliper-measured data. Applying the two-dimensional mathematical model
(described in Eq 5) the goal is to find the f constant which belongs to the C38 colon adenocarci-
noma and the treatment type. Starting with f = 1, we have investigated the goodness of the fit-
ting, using an iterative method. Our results for the case group (daily, quasi-continuous small
amount administration) and the control group (one big dose according to the protocol) are
VpIII=3 case ¼
p
6
 6:08  ðl  wÞ3=2 ! fpIII=3 case ¼ 6:08; ð6Þ
VpIII=3 control ¼
p
6
 3:68  ðl  wÞ3=2 ! fpIII=3 control ¼ 3:68: ð7Þ
Usage of this formula to calculate tumor volume from length and width values resulted in
much more precise approximation of the MRI-measured tumor volume than protocol-based
calculation. Numerical result can be found in Table 2, and Fig 5 presents graphical results.
To find the f constant for tumor growth without therapy (Phase I), first reliable tumor vol-
ume values had to be found, since there was no MRI measurement in Phase I. Beside tumor
diameters, tumor mass was measured and vascularization area was calculated in the case of the
removed tumors. We have investigated the relationship between MRI-measured tumor volume
and vascularization area (Phase III/3 case and control groups, 23rd (final) day of the experi-
ment) but no significant correlation was found (same results were published in the case of
Phase I [26] and Phase III/2 [23]). Examining the relationship between MRI-measured tumor
volume and tumor mass values, we have found a very strong linear correlation (R = 0.998, R2 =
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0.996, p< 0.0001). It means that knowing the tumor mass, tumor volume can be estimated
with suitable accuracy; hence the lack of MRI measurement can be replaced in the case of
Phase I. In the light of the above mentioned, linear curve fitting was carried out to find the
mathematical relationship between MRI-measured tumor volume and tumor mass (Phase
III/3 case and control groups). The resulted linear curve is
v ¼ 1047:7mþ 67:1; ð8Þ
Table 2. Experimental data of C38 mouse colon adenocarcinoma (tumor length, tumor width, tumor mass and tumor volume).
Phase III/3 control group (23rd day)
Code of the
mouse
Tumor lengtha
[mm]
Tumor widtha
[mm]
Tumor
massa [g]
Tumor volume caliper,
protocolb [mm3]
Tumor volume caliper, 2-D
modelb [mm3]
Tumor volume MRIc
[mm3]
C1 15.3 11.4 3.38 994 4439 3666
C2 26.5 18.4 8.67 4486 20746 9239
C3 13.0 9.4 2.11 574 2603 2081
C4 21.8 13.1 7.05 1871 9299 7335
C5 10.8 11.6 2.58 727 2702 2726
Phase III/3 case group (23rd day)
Code of the
mouse
Tumor lengtha
[mm]
Tumor widtha
[mm]
Tumor
massa [g]
Tumor volume caliper,
protocolb [mm3]
Tumor volume caliper, 2-D
modelb [mm3]
Tumor volume MRIc
[mm3]
E1 7.6 6.4 1.08 284 1080 1129
E2 9.1 6.6 0.98 390 1482 924
E3 10.7 10.0 2.34 927 3524 2707
E4 11.5 8.4 2.10 795 3023 2480
E5 10.3 8.4 1.95 674 2562 2226
E6 14.3 9.0 2.03 1223 4648 1929
E7 11.6 7.0 1.57 613 2329 1930
E8 19.7 14.3 5.00 3961 15052 5243
E9 8.4 6.8 0.86 362 1374 1013
Phase I (24th day)
Code of the
mouse
Tumor lengtha
[mm]
Tumor widtha
[mm]
Tumor
massa [g]
Tumor volume caliper,
protocolb [mm3]
Tumor volume caliper, 2-D
modelb [mm3]
Tumor volume MRId
[mm3]
n1 21.9 15.1 7.22 2497 8029 7631
n2 13.8 10.2 2.81 718 2230 3011
n3 15.1 10.8 4.34 881 2781 4614
n4 23.0 15.1 8.05 2622 8642 8501
n5 25.4 15.8 10.43 3170 10734 10995
n6 19.1 13.8 5.57 1819 5714 5903
n7 exit: 18th day
n8 exit: 23rd day
n9 20.7 14.9 5.65 2298 7232 5987
n10 17.5 12.1 4.93 1281 4114 5232
n11 18.2 12.3 3.91 1377 4472 4164
n12 23.1 13.7 5.97 2168 7517 6322
Data was measured at the final day of Phase I (24th day) and Phase III/3 (23rd day).
a Directly measured data (tumor length, tumor width, tumor mass)
b Estimated data (tumor volume measured by caliper, calculated according to Xenograft tumor model protocol or two-dimensional mathematical model)
c MRI-measured data (tumor volume calculated with flood fill algorithm)
d Evaluated data (“MRI” tumor volume calculated from linear curve fit (see Eq 8))
doi:10.1371/journal.pone.0142190.t002
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where v is tumor volume [mm3] andm is tumor mass [g]. Substituting tumor mass values
which were measured in Phase I into Eq 8, the corresponding tumor volume values can be eval-
uated (one can find numerical results in Table 2 Tumor volume “MRI” column; and graphical
results in Fig 6). The last step is to find the f constant of the two-dimensional mathematical
model for tumor growth without therapy (Phase I). Using the above mentioned iterative
method, the resulted equation is
VpI ¼
p
6
 2:55  ðl  wÞ3=2 ! fpI ¼ 2:55: ð9Þ
One can see from Table 2 that the goodness of the fit is different in the case of Phase I
(tumor growth without therapy) and in the case of Phase III/3 (tumor growth with antiangio-
genic therapy). Investigating the results of Phase III/3 one can observe that the two-dimen-
sional mathematical model has good estimation property when the tumor width and length
values are small; however, for large tumor diameter values the estimation could result in
Fig 5. Validation of caliper-measured data. The figure shows the results of a mouse (C4) from control group (first row), and a mouse (E9) from case group
(second row). The first column shows the tumor values which were calculated using the two-dimensional mathematical model; the second column represents
the protocol-based tumor volumes. In each case the reference value is the MRI-measured tumor volume. One can see that the two-dimensional
mathematical model fits to the MRI-measured values, while the protocol-based values present totally different curve.
doi:10.1371/journal.pone.0142190.g005
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significant error, the estimated value is greater than the measured one (outliers are E8, C2). In
the case of Phase I, no similar problem occurs; the two-dimensional mathematical model can
handle great values as well (e.g. n5). This problem can be explained by our observation, namely
tumors which were grown without therapy have more symmetric and solid closed shape, in
contrast to tumors which were grown under antiangiogenic therapy. We have found that mice
which have received therapy had tumor with irregular, and in several cases berry-shaped struc-
ture, especially when reaching large volume. In that case—even though all the three diameters
can be measured—the estimation of the volume has quite a large error. A 3-D illustration can
be found in Fig 7.
Comparing the effectiveness of bevacizumab administration in the case
of protocol-based and quasi-continuous therapies
The results of the three investigated cases using C38 mouse colon adenocarcinoma (Phase I,
Phase III/3 control group, and Phase III/3 case group) were compared using tumor volume val-
ues fromMRI measurements (Phase III/3 control and case groups, 23rd day) and evaluated
data (Phase I “MRI” tumor volume calculated from linear curve fit, 24th day). One can find
datasets in the last column of Table 2. Normality was investigated with one-sample
Fig 6. Evaluation of Phase I tumor volume values. “Measured data” is the MRI-measured tumor volume—tumor mass pairs on the 23rd day of Phase III/3
(case and control group). For this dataset, linear curve fitting was carried out (“fitted linear curve”) to find the mathematical relationship between MRI-
measured tumor volume and tumor mass. Substituting tumor mass values which were measured on the 24th day of Phase I to the equation of the resulted
curve, the corresponding tumor volume values can be evaluated (“evaluated data”).
doi:10.1371/journal.pone.0142190.g006
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Kolmogorov-Smirnov test; each sample has normal distribution (ppI = 0.883, ppIII/3_case =
0.716, ppIII/3_control = 0.869). Homogeneity of variance was examined with Levene’s test; the
sample variances are equal (p = 0.052).
To compare more than two samples, ANOVA test was applied. We have found that there is
significant difference between the means of the samples (p = 0.002, using 0.05 level of signifi-
cance). Pairwise comparison was done by Tukey’s honest significant difference test to find
those samples, which have significantly different means. The post hoc test resulted in the fol-
lowing. Phase I and Phase III/3 control groups are not significantly different (p = 0.572), while
Phase I and Phase III/3 control groups are significantly different (p = 0.002). This means that
mice which were treated with the recommended bevacizumab protocol (one 200 μg bevacizu-
mab dose for an 18-day therapy) did not have significantly smaller tumor volume than mice
which did not receive therapy at all. However mice which were treated with a quasi-continuous
therapy (one-tenth dose of control dose spread over 18 days, i.e. 1.11 μg bevacizumab every
day) had significantly smaller tumor volume than mice that did not receive therapy. Average of
tumor volumes for every measurement days of the experiment can be seen in Fig 8.
To validate our results which come from the experiments where mouse tumor vascularization
was inhibited with humanized VEGF, we evaluated the results of Phase IV, where immunocom-
promized (SCID) mice were used with human colorectal adenocarcinoma (HT-29) xenografts.
In this phase, control group members received no treatment; case1 group members received one
200 μg bevacizumab dose; while case2 group members received 1.11 μg bevacizumab daily for 15
days (the total dose of case2 group members is the one-twelfth dose of case1 group members).
For the most precise result, tumor mass values, which were measured at the end of the experi-
ment, were compared in the statistical analysis. One can find datasets in Table 3. Pursuant to
one-sample Kolmogorov-Smirnov test, each sample has normal distribution (ppIV_control = 0.981,
ppIV_case1 = 0.998, ppIV_case2 = 0.854). Levene’s test showed that the sample variances are equal
Fig 7. Illustration for tumor with irregular structure (berry-shaped). a) berry-shaped tumor; b) x-diameter of the tumor; c) y-diameter of the tumor; d) z-
diameter of the tumor; e) berry-shaped tumor with ellipsoidal estimation. Even though all the three diameters can be measured, the estimation of the volume
has quite a large error.
doi:10.1371/journal.pone.0142190.g007
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(p = 0.108). The means of the samples arempIV_control = 0.65,mpIV_case1 = 0.70,mpIV_case2 = 0.46.
ANOVA test showed significant difference between these means (p = 0.041, using 0.05 level of
significance). Tukey’s HSD test resuled in significant difference between case1 and case2 groups
(p = 0.038). This means that the daily treatment with one-twelfth total dose resulted in signifi-
cantly smaller tumors than the protocol-based treatment.
Fig 8. Average of tumor volumes for every measurement days of the experiment in the case of Phase I, Phase III/3 control and Phase III/3 case
group. The significant difference between quasi-continuous therapy (Phase III/3 case group) and tumor growth without treatment (Phase I) was proved with
statistical analysis as well.
doi:10.1371/journal.pone.0142190.g008
Table 3. Experimental data of human colorectal adenocarcinoma (HT-29) xenografts (tumor mass).
Phase IV control group (23rd
day) tumor mass [g]
Phase IV case1 group (23rd
day) tumor mass [g]
Phase IV case2 group (23rd
day) tumor mass [g]
0.73 0.96 0.64
0.66 0.54 0.60
0.39 0.72 0.42
0.81 0.80 0.37
1.13 0.43
0.40 0.45
0.80 0.41
0.61 0.53
0.37 0.29
doi:10.1371/journal.pone.0142190.t003
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Discussion
Since 2004, the target therapy of bevacizumab (Avastin) is widely used to treat colorectal [9],
kidney [10], cervical [34], ovarian [35], non-small cell lung cancers [5], melanoma [14] and
certain brain tumors (e.g. recurrent glioblastoma (rGBM) [36]) as a first or second line treat-
ment, usually in combination with chemo- or immunotherapy. The usual administration is via
intravenous infusion; once every 2 or 3 weeks. The dose depends mainly on weight. However,
most serious questions are: for how long and continuous or not? The most recent ESMO
(European Society for Medical Oncology) consensus guidelines suggest that treatment discon-
tinuation or maintenance are feasible options after 4–6 months of full-dose first-line therapy to
treat colon and rectal adenocarcinoma [37]. However, if the treatment is lengthy, the problem
of side-effects also has to be considered. To overcome all of these difficulties (continuity of the
administration and side-effects), model identification should be determined and then a control
algorithm (controller) can be designed for the created mathematical model. Of course, for the
closed-loop design frequent and precise tumor volume measuremets are required, thus the
problem of tumor volume measurement has to be solved as well. Finding the mathematical
relationship between MRI-measured tumor volume and tumor mass creates the possibility to
estimate tumor volume from caliper-measured data. However, it has to be taken into consider-
ation that in several cases using antiangiogenic therapy, tumor shape is irregular (berry-
shaped). Consequently, when tumor mass data is unavailable (during the experiment), tumor
volume value can be validated with MRI; in that way outlier data points (which were calculated
using the two-dimensional mathematical model) can be filtered out. In clinical practice, the
determination of the tumor size (volume) is done by MRI and/or CT, but this is for the purpose
of validating the effectiveness of the treatment, and therefore it is not a continuous monitoring.
In the concept of model-based treatment, a continuous and precise tumor volume monitoring
is needed concerning which, may be possible in the near future by nanotechnology [38].
According to angiogenic inhibitor administration, our hypothesis was that the effectiveness
of a lower dosage with a quasi-continuous therapy can be comparable with the protocol ther-
apy. Nevertheless the result of our study shows that the effectiveness is even better. Conse-
quences are manifold. First of all, our hypothesis according to the importance of
administration is proved. The effectiveness of the quasi-continuous (daily) 1/180 dosage (1.11
μg relative to 200 μg) using C38 mouse colon adenocarcinoma was more effective than one
large dose. We found the same result for human colorectal adenocarcinoma (HT-29) xeno-
grafts. The explanation of the effectiveness of low dose VEGF therapy is the following ([39–
44]). Healthy tissues have efficient vasculature and effective blood supply due to the balance of
proangiogenic and antiangiogenic factors. When tumor cells become able to produce proangio-
genic factors (the process is called as angiogenic switch), it will result in abnormal and ineffi-
cient vascular network (with high vascular permeability and poor perfusion) due to the hurried
process of vessel formation. Tumor growth can take place under such conditions; however
delivery of chemotherapeutic drugs is obstructed. Hence, the first step has to be the vasculature
normalization with the reconstruction of the balance of pro- and antiangiogenic factors. This
means that continuous, low dose antiangiogenic factor (VEGF) administration is needed. This
creates the possibility of further efficient therapeutic agent use (if any) or assists the more effec-
tive direct antitumoral effect of bevacizumab.
Similarly, Zhang et al. [45] have found that the combination of low-dose cyclophosphamide
and ginsenoside Rg3 therapy can be more effective than the normal administration. Although
the low dose bevacizumab therapy is well known in the literature, we found no article (in the
English literature) regarding very low dose and quasi-continuous bevacizumab therapy, as
used in our study. Secondly, the aspect of side-effects are not inconsiderable. For example, one
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of the main reasons why the US FDA revoked the approval of Avastin for treating advanced
breast cancer is the high rate of side-effects when bevacizumab was applied [46]. Typical side-
effects and adverse events are arterial and venous thromboembolic events, bleeding, hyperten-
sion, febrile neutropenia, infections, proteinuria, mucositis, and hand-foot syndrome. Using an
extremely low dosage (as in our study), there is a high probability that these adverse effects can
be minimized.
In our study, we applied a two-dimensional mathematical model and determined the corre-
sponding tumor- and therapy-specific constants in the three investigated cases (C38 colon ade-
nocarcinoma growth without therapy, C38 colon adenocarcinoma growth with protocol-based
bevacizumab therapy and C38 colon adenocarcinoma growth with quasi-continuous bevacizu-
mab therapy). This helps to calculate accurate tumor volume from caliper measured data
which will be useful for further animal experiments and as a consequence no small MRI mea-
surements will be needed. In addition, we have found that the quasi-continuous administration
of bevacizumab is effective against tumor growth of C38 colon adenocarcinoma, in contrast to
protocol-based treatment. Considering the possibility of precise tumor volume determination
and the effective quasi-continuous drug administration, it opens a new treatment choice based
on closed-loop control. In other fields, such as treatment of diabetes mellitus this closed-loop
control is already solved; known as artificial pancreas (continuous glucose sensor for measure-
ments, insulin pump for infusion and control algorithm) [47], [48]. Similarly, we may have the
possibility to a) measure the tumor volume using nanotechnology, b) create a pump for drug
administration and c) design control algorithms for specific tumor types. Controller-based
therapy has the obvious advantage against e.g. constant low-dose therapy because in the case of
controller-based administration, the control signal (administration dose) can vary from zero to
the maximum tolerable dose according to the perceived tumor volume. In this way, the tar-
geted therapy can be used in a much more individualized form.
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